GlaxoSmithKline Pharmaceuticals India Q4 FY26 Results: PAT Rs 277.86 Crore Up 5.7 Percent Dividend Rs 57 Per Share Record Date May 29
- May 14, 2026
- Posted by: Kashish Aggarwal
- Category: News
GlaxoSmithKline Q4 FY26 results, announced on May 13, 2026, showed consolidated PAT of Rs 277.86 crore, up 5.7% YoY from Rs 262.87 crore in Q4 FY25. The GlaxoSmithKline Q4 FY26 board also recommended a final dividend of Rs 57 per equity share for FY26, with record date May 29, 2026 and payment expected on or after July 1, 2026. Investors tracking GlaxoSmithKline Q4 FY26 results will find complete analysis and FY27 outlook below.
Click Here – Get Free Investment Predictions
GlaxoSmithKline Q4 FY26 Key Financial Highlights
| Metric | Q4 FY26 | Q4 FY25 / YoY Change |
|---|---|---|
| Consolidated PAT | Rs 277.86 crore | Rs 262.87 crore (Q4 FY25) | +5.7% YoY |
| FY26 Final Dividend | Rs 57 per equity share | Record date May 29, 2026 | Payment July 1, 2026+ |
| NSE Ticker | GLAXO | Sector: Pharmaceuticals | UK GSK Group |
Screen the best stocks on the Univest Screener.
GlaxoSmithKline Q4 FY26 Performance Analysis
The GlaxoSmithKline Q4 FY26 consolidated PAT growth of 5.7% YoY to Rs 277.86 crore reflects stable demand for prescription pharma products in India. GlaxoSmithKline Q4 FY26 performance was driven by its core vaccine and pharmaceutical franchise, including Augmentin, Calpol, and Sensodyne brands. The company is a subsidiary of the UK-listed GSK plc.
The GlaxoSmithKline Q4 FY26 dividend of Rs 57 per equity share (face value Rs 10) represents a dividend yield of approximately 2.4% at prevailing prices. The GlaxoSmithKline Q4 FY26 result was announced at the company’s 101st AGM preparation stage. Investors in GlaxoSmithKline Q4 FY26 should note the board’s consistent dividend policy as a marker of operational confidence.
GlaxoSmithKline FY27 Outlook
Post GlaxoSmithKline Q4 FY26, management focus will be on growing the prescription pharma, vaccines, and consumer healthcare portfolio in India. India’s pharmaceutical sector continues to grow at 9-11% per annum, providing structural support. Track GlaxoSmithKline Q4 FY26 analyst views on the Univest Screener.
Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.
Frequently Asked Questions on GlaxoSmithKline Q4 FY26
What is GlaxoSmithKline Q4 FY26 PAT?
Ans. GlaxoSmithKline Q4 FY26 consolidated PAT was Rs 277.86 crore, up 5.7% YoY from Rs 262.87 crore in Q4 FY25.
What is GlaxoSmithKline Q4 FY26 dividend?
Ans. The GlaxoSmithKline Q4 FY26 board recommended a final dividend of Rs 57 per equity share for FY26. Record date is May 29, 2026 and payment is due on or after July 1, 2026 post AGM approval.
When was GlaxoSmithKline Q4 FY26 announced?
Ans. GlaxoSmithKline Q4 FY26 results were announced on May 13, 2026, through the company’s board meeting and exchange filings with BSE and NSE.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.
